(2025) ๋ณ‘๋ฆฌ1(A) - 4.1 Neoplasia ์—์„œ ์ด์–ด์ง.

๊ธฐ์–ตํ•˜์ž!

  • sarcoma = ๊ฐ„์—ฝ ์œ ๋ž˜์˜ ์•…์„ฑ ์ข…์–‘
  • carcinoma = ์ƒํ”ผ์„ธํฌ ์œ ๋ž˜์˜ ์•…์„ฑ ์ข…์–‘ (Adeno-, Squamous cell, Transitional cell)

4. ์ „์ด(Metastasis)

๐ŸŸข ์ „์ด์˜ ์ค‘์š”์„ฑ (The Significance of Metastasis)

  • ์ „์ด(Metastasis) : ์›๋ฐœ ์ข…์–‘์—์„œ ๋‹ค๋ฅธ ๋จผ ์žฅ๊ธฐ๋กœ ์ข…์–‘์ด ํผ์ง€๋Š” ๊ฒƒ.
  • ์•” ํ™˜์ž๋Š” ๋Œ€๋ถ€๋ถ„ ์›๋ฐœ ์ข…์–‘๋ณด๋‹ค๋Š” ์ค‘์š”ํ•œ ์žฅ๊ธฐ๋กœ ์ „์ด๋˜๋ฉด์„œ ์ƒ๋ฆฌ์  ๊ธฐ๋Šฅ ๋ถ€์ „์œผ๋กœ ์‚ฌ๋ง์— ์ด๋ฆ„. (Primary tumor๋Š” ํ™˜์ž์˜ ์ฃฝ์Œ์— ์ง์ ‘์ ์ธ ์—ฐ๊ด€์ด ์—†์„ ๋•Œ๊ฐ€ ๋งŽ๋‹ค)
  • ๋Œ€๋ถ€๋ถ„ ์‹ฌ์žฅ, ๋‡Œ, ํŽ˜์ฒ˜๋Ÿผ ์ค‘์š”ํ•œ ์žฅ๊ธฐ๋กœ ์ „์ด๋˜์–ด ์ฃฝ์Œ์— ์ด๋ฅธ๋‹ค!

<์•Œ์•„๋‘˜ ๊ฒƒ> Metastasis is a highly inefficient process!

  • โ€˜์ „์ดโ€™๋ž€ ๋งค์šฐ ๋น„ํšจ์œจ์ ์ธ ๊ณผ์ •์ด๋‹ค: 1%๋„ ์•ˆ ๋˜๋Š” ์•„์ฃผ ๋‚ฎ์€ ํ™•๋ฅ ๋กœ ์นจ์Šตํ•˜๊ณ , ๋˜ ํ˜ˆ๊ด€์œผ๋กœ ๋“ค์–ด๊ฐ€๊ณ , ๋˜ ๋ฉ€๋ฆฌ๊นŒ์ง€ ์ด๋™ํ•˜์—ฌ, ๋˜ ๊ฑฐ๊ธฐ์„œ ์ •์ฐฉํ•˜๊ธฐ๋ž€.. ์ •๋ง ๋ณต์žกํ•˜๊ณ  ๋‚ฎ์€ ํ™•๋ฅ .
  • ๊ทธ๋งŒํผ ์˜ค๋ž˜ ๊ฑธ๋ฆฌ๊ณ ,
  • ๊ทธ๋งŒํผ ๊ณต๊ฒฉ์ ์ธ ์• ๋“ค์ด๋ผ๋Š” ๋œป.

๐ŸŸข ์ „์ด์˜ ๊ณผ์ • (The Metastatic Cascade)

<Overview>

Metastatic Cascade<
1๏ธโƒฃ Local Invasion
(๊ตญ์†Œ์  ์นจ์Šต)
์›๋ฐœ ์ข…์–‘์—์„œ ๋–จ์–ด์ ธ ๋‚˜์™€ ์ฃผ๋ณ€ ๊ธฐ์งˆ์„ ์นจ์Šต.
^
โ‘  ์—ฐ๊ฒฐ๋œ junction์„ ๋Š์–ด์•ผ ํ•จ.
- E-cadherin๊ณผ ๊ฐ™์€ ๋ถ€์ฐฉ ๋ถ„์ž(adhesion molecule)์„ ๋Š์Œ.
โ‘ก Basement membrane๊ณผ ECM์˜ ๊ฒฐํ•ฉ์กฐ์ง์„ ๋šซ์–ด์•ผ ํ•จ.
- ํšจ์†Œ(protease) ํ™œ์šฉ : ๋Œ€ํ‘œ์ ์œผ๋กœ MMPs(matrix metalloproteinases)์„ ๋ฐœํ˜„ํ•ด์„œ ์ฃผ๋ณ€์„ ๋…น์ž„.
ใ„ด EMT
(Epithelial-Mesenchymal Transition)
- ์ƒํ”ผ์„ธํฌ๊ฐ€ junctional protein์„ ์žƒ์–ด๋ฒ„๋ฆฌ๊ณ , ๊ฐ„์—ฝ์„ธํฌ์ฒ˜๋Ÿผ ๋ฐ”๋€Œ๋Š” ๊ฒƒ (์„œ๋กœ ๋ถ™์œผ๋ ค๋Š” ์„ฑ์งˆ์„ ์žƒ๊ณ  ๋…๋ฆฝ์ ์œผ๋กœ ์กด์žฌ)
- EMT๊ฐ€ ์นจ์Šต๊ณผ ์ „์ด์— ํ•„์ˆ˜์ ์ธ ๊ฒƒ์€ ์•„๋‹˜.
- ๋‹ค๋งŒ ๊ตญ์†Œ์  ์นจ์Šต์— ์œ ๋ฆฌํ•˜๊ฒŒ ๋˜๋Š” ๊ฒƒ.
2๏ธโƒฃ Intravasation
& Survival in Circulation
ํ˜ˆ๊ด€์ด๋‚˜ ๋ฆผํ”„๊ด€ ๋‚ด๋กœ ๋“ค์–ด์˜ด. โ†’ ํ˜ˆ๋ฅ˜๋ฅผ ํƒ€๊ณ  ์ˆœํ™˜ํ•˜๋ฉด์„œ ๋ฉด์—ญ์„ธํฌ๋กœ๋ถ€ํ„ฐ ์‚ด์•„๋‚จ์•„์•ผ ํ•จ.
^- ํ˜ˆ๊ด€ ์ฃผ๋ณ€๊นŒ์ง€ ์˜ฌ ๋งŒํผ ์ปค์ง„ ์ข…์–‘ ๋ฉ์–ด๋ฆฌ๋Š” ํ•„์—ฐ์ ์œผ๋กœ ์˜์–‘๋ถ„ ๊ณต๊ธ‰์ด ํ•„์š”.
- ์ข…์–‘์„ธํฌ๊ฐ€ ์‹ ํ˜ธ๋ฅผ ๋ณด๋‚ด๋ฉด ํ˜ˆ๊ด€๋‚ดํ”ผ์„ธํฌ๊ฐ€ migrationํ•ด์„œ ์‹ ์ƒ ํ˜ˆ๊ด€์„ ํ˜•์„ฑ.
- Angiogenesis๋กœ ํ˜•์„ฑ๋œ ํ˜ˆ๊ด€์€ ํ›จ์”ฌ ์–‡๊ณ  ๋ถˆ์™„์ „ํ•ด์„œ ์ข…์–‘์„ธํฌ๊ฐ€ ๋šซ๊ณ  ๋“ค์–ด๊ฐ€๊ธฐ ํ›จ์”ฌ ์‰ฝ๋‹ค. (๋™๋งฅ์„ฑ ํ˜ˆ๊ด€ > ์ •๋งฅ์„ฑ ํ˜ˆ๊ด€ > ์‹ ์ƒ ํ˜ˆ๊ด€)
3๏ธโƒฃ Extravasation
& Colonization
ํ˜ˆ๊ด€ ๋ฐ–์œผ๋กœ ๋‚˜์˜ด. โ†’ ์ƒˆ๋กœ์šด ํ™˜๊ฒฝ์— ์ ์‘, ์ฃผ๋ณ€ ํ™˜๊ฒฝ(microenvironment)์˜ ๋„์›€์„ ๋ฐ›์•„ ํฐ ๋ฉ์–ด๋ฆฌ๋ฅผ ํ˜•์„ฑ
^- ํ˜ˆ๊ด€์„ ํƒ€๊ณ  ๋‹ค๋‹ˆ๋˜ ์ข…์–‘์„ธํฌ๊ฐ€ ๋ณดํ†ต ๊ฐ€์žฅ ์‰ฝ๊ฒŒ ๋„๋‹ฌํ•˜๋Š” ๊ณณ์ด ๋ฆผํ”„์ ˆ. (์ฒดํ‘œ๋‚˜ ๋ณต๊ฐ•, ํ‰๊ฐ•์— ์žˆ๋Š” ์ž‘์€ ๋ฆผํ”„์†Œ์ ˆ๋“ค) โ‡’ ํŠนํžˆ ๋ฆผํ”„์ ˆ์˜ capsule ์•„๋ž˜ ๊ณต๊ฐ„.
- ๋ฆผํ”„๊ตฌ๋ฅผ ๋งŒ๋“ค๊ณ  ๊ณ„์† ๋ฟœ์–ด๋‚ด๋Š” ๊ธฐ๊ด€์ด๋‹ค ๋ณด๋‹ˆ ์ „์ด๊ฐ€ ๋”์šฑ ์šฉ์ดํ•จ.
- ๋‹ค๋งŒ, ๋ฆผํ”„์ ˆ ์•ˆ์—์„œ ์‚ด์•„๋‚จ๊ธฐ๋Š” ์‰ฝ์ง€ ์•Š์Œ : lymphocytes๋“ค์ด activeํ•˜๊ฒŒ ๊ณต๊ฒฉํ•จ, ์—ฌ๊ธฐ์„œ ์‚ด์•„๋‚จ์œผ๋ฉด ์ง„์งœ ํŠผํŠผํ•œ ์• ๋“ค.

๐ŸŸข ์ „์ด์˜ ๊ฒฝ๋กœ (Pathways of Tumor Spread)

  • Carcinoma๋Š” ๋ฆผํ”„๊ด€์„ ํ†ตํ•œ ์ „์ด, Sarcoma๋Š” ํ˜ˆ๊ด€์„ ํ†ตํ•œ ์ „์ด๊ฐ€ ์ผ๋ฐ˜์ ์ด๋‹ค. (๊ฒฝํ–ฅ์„ฑ, ์นœํ™”์„ฑ)
  • Transcoelomic Spread (Seeding) :
    • ํ˜ˆ๊ด€์ด๋‚˜ ๋ฆผํ”„๊ด€์„ ํ†ตํ•˜์ง€ ์•Š๊ณ , ์–ด๋”˜๊ฐ€์— ์ง์ ‘ ๋‹ฌ๋ผ๋ถ™์–ด์„œ ์ปค์ง€๋‹ค๊ฐ€ ๋–จ์–ด์ ธ ๋‚˜๊ฐ€๋ฉด์„œ ์ฆ์‹ํ•˜๋Š” ๋ฐฉ์‹. Mesothelioma(์ค‘ํ”ผ์•”), ovarian carcinoma(๋‚œ์†Œ์•”) ๋“ฑ์ด ์žˆ์Œ.
      • ๋ณดํ†ต ์œ„, ์†Œ์žฅ, ๋Œ€์žฅ์˜ ์ ๋ง‰์—์„œ ์ข…์–‘์ด ๋ฐœ์ƒํ•˜๋ฉด ๋ฐ–์œผ๋กœ ๋‚˜๊ฐ€๊ธฐ ์œ„ํ•ด ๋‘๊บผ์šด ๊ทผ์œก์ธต์„ ๋šซ์–ด์•ผ ํ•˜๋Š” ๋ฐ˜๋ฉด,
      • Mesothelioma(์ค‘ํ”ผ์•”)์€ ๋งจ ๋ฐ”๊นฅ์ชฝ ์žฅ๋ง‰๋ฉด์— ์žˆ๋Š” ์„ธํฌ์—์„œ ์ƒ๊ธฐ๋Š” ์ข…์–‘์ด์–ด์„œ ์ฆ์‹์— ๊ณต๊ฐ„ ์ œ์•ฝ์ด ์—†์Œ โ‡’ ๊ณ„์† ์ปค์ง€๋‹ค๊ฐ€ ๋š ๋–จ์–ด์ ธ์„œ ๋ณต๊ฐ•๋‚ด ๋‹ค๋ฅธ ์žฅ๊ธฐ์˜ ์žฅ๋ง‰๋ฉด์— ๋ถ™์œผ๋ฉด์„œ ์ฆ์‹ํ•จ.
    • ์ด๋Ÿฐ ๊ฒฝ์šฐ ์—ฌ๋Ÿฌ ์žฅ๊ธฐ์— ๋‹ฌ๋ผ๋ถ™์–ด์„œ ๋™์‹œ๋‹ค๋ฐœ์ ์œผ๋กœ ์„ฑ์žฅํ•ด์„œ ์›๋ฐœ์„ฑ ์ข…๊ดด๋ฅผ ๊ตฌ๋ณ„ํ•˜๊ธฐ ์–ด๋ ค์›€
      (โ‡’ carcinomatosis : ์›๋ฐœ ๋ถ€์œ„๋Š” ์•Œ ์ˆ˜ ์—†์œผ๋‚˜, ์ƒํ”ผ์„ธํฌ์„ฑ ์ข…์–‘์ด ์—ฌ๋Ÿฌ ๋ณต๊ฐ•/ํ‰๊ฐ• ์žฅ๊ธฐ์˜ ์žฅ๋ง‰๋ฉด์— ๋ถ™์–ด์žˆ๋Š” ๊ฒƒ.)

5. ์ข…์–‘์˜ Systemic Effect

์ „์ด๊ฐ€ ์–ด๋–ป๊ฒŒ ์ผ์–ด๋‚˜๋Š”์ง€ ๋ฐฐ์› ์œผ๋‹ˆ ์ด์ œ ์ข…์–‘์ด ๋ชธ์— ์‹ค์ œ๋กœ ์–ด๋–ค ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š”์ง€ ๋ณด์ž.

  • ๊ตญ์†Œ์  ์˜ํ–ฅ = ๋ฐœ์ƒ ๋ถ€์œ„์— ๋ฏธ์น˜๋Š” ๋ฌผ๋ฆฌ์ ์ธ ์˜ํ–ฅ
  • ์ „์‹ ์  ์˜ํ–ฅ = ์ข…์–‘์ด ์—†๋Š” ๋ถ€์œ„๊นŒ์ง€ ์ „์‹ ์ ์œผ๋กœ ์˜ํ–ฅ์„ ๋ฏธ์นจ

Direct effect (= Local effect, ๊ตญ์†Œ์  ์˜ํ–ฅ)

  • ์ •์ƒ ์กฐ์ง์„ ๋Œ€์ฒดํ•จ์œผ๋กœ์จ ์ •์ƒ ์กฐ์ง์˜ ๊ธฐ๋Šฅ์„ ์ €ํ•ดํ•จ.
  • ์ฃผ๋ณ€๋ถ€๋ฅผ ๋ง‰๊ฑฐ๋‚˜(obstruction), ์••๋ฐ•ํ•˜๊ฑฐ๋‚˜(compression), ๋นˆ(hollow) ์žฅ๊ธฐ๋ฅผ ํ„ฐ๋œจ๋ ค์„œ(rupture) ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ์Œ.
    • ex) ์†Œํ™”๊ด€์— ์ƒ๊ธด ์ข…์–‘ ๋•Œ๋ฌธ์— ๋‚ด๊ฐ•์ด ๊ฝ‰ ๋ง‰ํ˜€์„œ ์Œ์‹๋ฌผ์ด ์ž˜ ๋„˜์–ด๊ฐ€์ง€ ๋ชปํ•จ.
  • ๊ณต๊ฐ„์  ์ œ์•ฝ์„ ๊ฐ€์žฅ ๋งŽ์ด ๋ฐ›๋Š” ์žฅ๊ธฐ๋Š” brain โ†’ ์—ฌ๊ธฐ์„œ ์ข…์–‘์ด ์ƒ๊ธฐ๋ฉด ์ฃผ๋ณ€์œผ๋กœ์˜ ๋ฌผ๋ฆฌ์  ์••๋ฐ•์ด ๋งค์šฐ ์‹ฌํ•จ.

Paraneoplastic Syndromes (= Systemic effect)

์ข…์–‘์˜ systemic effect. (์‚ฌ๋žŒ์—์„œ๋Š” ๋งŽ๊ฒŒ๋Š” 75%์˜ ์•” ํ™˜์ž๊ฐ€ systemic effect๋ฅผ ๋ฐ›๊ณ  ์žˆ๋‹ค๊ณ  ํ•œ๋‹ค)

Organ SystemSyndromeAssociated Neoplasms
EndocrineHypercalcemia of malignancyLymphoma, Apocrine gland carcinoma of anal sac(AGASACA), Mammary carcinoma, Thymoma, Others
HypoglycemiaHepatocellular carcinoma, Islet cell carcinoma, Leiomyoma/leiomyosarcoma, Plasma cell tumor, Others
Ectopic ACTHLymphoma
CutaneousParaneoplastic pemphigusLymphoma
AlopeciaPancreatic carcinoma (cat), Others
Necrolytic migratory erythemaGlucagonoma
HematologicHypergammaglobulinemiaMultiple myeloma
AnemiaMany neoplasms
ErythrocytosisRenal carcinoma
NeurologicMyasthenia gravisThymoma, Others
Peripheral neuropathyInsulinoma, Others
RenalGlomerulonephritisMultiple myeloma, Polycythemia vera, Others
GastrointestinalGastroduodenal ulcerationMast cell tumors, Gastrinoma
MiscellaneousHypertrophic osteopathyThoracic masses, Other thoracic masses, Urinary bladder rhabdomyosarcoma

์ „ํ˜€ ์ƒ๊ด€ ์—†์–ด ๋ณด์ด๋Š” ์žฅ๊ธฐ์—๋„ ์˜ํ–ฅ์„ ์ค„ ์ˆ˜ ์žˆ๋‹ค๋Š” ๊ฑธ ์•Œ์•„๋‘์ž. (์นผ์Š˜ ๋†๋„์˜ ๋น„์ •์ƒ์  ์ฆ๊ฐ€ = ์‹ ์žฅ, ๋ถ€๊ฐ‘์ƒ์„  ๋“ฑ์˜ ๋ฌธ์ œ์ผ ์ˆ˜๋„ ์žˆ์ง€๋งŒ ํ•ญ๋ฌธ๋‚ญ ์ข…์–‘ ๋“ฑ ์ข…์–‘ ๋•Œ๋ฌธ์ผ ์ˆ˜๋„ ์žˆ์Œ)

Paraneoplastic syndromes 1: Cachexia
  • ์‹ฌ๊ฐํ•œ ์ฒด์ค‘ ๊ฐ์†Œ์™€ ์šด๋™ ๋Šฅ๋ ฅ ์†Œ์‹ค.
  • ๊ทผ์œก๊ณผ ์ง€๋ฐฉ์„ ๋‹ค ์žƒ์–ด๋ฒ„๋ฆผ. (๋ณดํ†ต ๊ตถ์œผ๋ฉด ์ง€๋ฐฉ๋งŒ ๋น ์ง€๋Š”๋ฐ, cachexia๋Š” ๊ทผ์œก/์ง€๋ฐฉ ๋‹ค ๋น ์ง.)
  • โ‡’ ๋”ฐ๋ผ์„œ ์šด๋™ ๋Šฅ๋ ฅ๋„ ์ƒ๋‹นํžˆ ๊ฐ์†Œ๋œ๋‹ค.
Paraneoplastic syndromes 2: Endocrinopathies
  • ์ข…์–‘์„ธํฌ๋Š” ํ˜ธ๋ฅด๋ชฌ์„ ์ •์ƒ๋ณด๋‹ค ํ›จ์”ฌ ๊ณผ๋ฐœํ˜„์‹œํ‚ฌ ์ˆ˜ ์žˆ์Œ. (์ƒ˜์ข…์–‘์ด ์•„๋‹ˆ๋”๋ผ๋„)
  • Humoral Hypercalcemia of Malignancy (HHM) : ์ข…์–‘์ด PTHrP (Parathyroid hormone-related peptide)๋ฅผ ๋ถ„๋น„ํ•ด์„œ ๋ฐœ์ƒ.
    • Parathyroid hormone์€ ์›๋ž˜ ๋ผˆ๋ฅผ ๊ฐ‰์•„์„œ ๋ผˆ์—์„œ ์นผ์Š˜์„ ์žฌํก์ˆ˜ โ‡’ ํ˜ˆ์ค‘ ์นผ์Š˜ ๋†๋„๋ฅผ ๋†’์ด๋Š” ์—ญํ• .
    • ์ข…์–‘์„ธํฌ๊ฐ€ Parathyroid hormone๊ณผ ๋น„์Šทํ•œ ์—ญํ• ์„ ํ•˜๋Š” peptide๋ฅผ ๋ถ„๋น„ํ•˜๋ฉด โ†’ ๋ผˆ์™€ ์‹ ์žฅ์—์„œ ์นผ์Š˜ ์žฌํก์ˆ˜๋ฅผ ์ด‰์ง„ โ†’ ํ˜ˆ์ค‘ ์นผ์Š˜ ๋†๋„๋ฅผ ๋น„์ •์ƒ์ ์œผ๋กœ ๋†’์ž„.
    • ๊ฐœ์—์„œ adenocarcinoma of anal sac, lymphoma, multiple myeloma์—์„œ ๊ฐ€์žฅ ์ž˜ ๊ด€์ฐฐ๋จ.
Paraneoplastic syndromes 3: Skeletal & Hematologic
  • ๊ทผ๊ณจ๊ฒฉ๊ณ„๋‚˜ ํ˜ˆ์•ก์—๋„ ์˜ํ–ฅ์„ ๋ฏธ์น  ์ˆ˜ ์žˆ๋‹ค. ์›๋ฐœ ๋ถ€์œ„์™€ ์ƒ๊ด€ ์—†์–ด ๋ณด์ด๋Š” ์˜ํ–ฅ๋„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์Œ์„ ๊ธฐ์–ตํ•˜์ž.
  • Hypertrophic Osteopathy (๋น„๋Œ€์„ฑ ๊ณจ๋ณ‘์ฆ) : ์ƒˆ๋กœ์šด ๋ผˆ๋ฅผ ๊ณผ๋„ํ•˜๊ฒŒ ์ƒ์„ฑ (์‹ค์ œ๋กœ ์„ฑ์ˆ™ํ•œ ๋ผˆ๋Š” ๋ณ„๋กœ ์—†๊ณ  ๊ฒฐํ•ฉ์กฐ์ง์œผ๋กœ ๋งŽ์ด ์ฑ„์›€)
    • X-ray ์ƒ ์—ฐ๋ถ€์กฐ์ง ์ด์ƒ์˜ ์กฐ์˜ ์ฆ๊ฐ•์ด ๋ณด์ž„.
    • ์–‘์ธก ๋Œ€์นญ์„ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒƒ๋„ ํŠน์ง•. (์–‘์ธก ๋Œ€์นญ = systemic, ํ˜ˆ์•ก/ํ˜ธ๋ฅด๋ชฌ ๋ฌธ์ œ์ผ ๊ฐ€๋Šฅ์„ฑ โ†‘)

  • Myelofibrosis (๊ณจ์ˆ˜์„ฌ์œ ํ™”) : ๊ณจ์ˆ˜ ๋‚ด์— ๋น„์ข…์–‘์„ฑ fibroblast๊ฐ€ ๊ณผ๋„ํ•˜๊ฒŒ ์ฆ์‹, ๊ณจ์ˆ˜๊ฐ•์ด ์„ฌ์œ ์กฐ์ง์œผ๋กœ ๋Œ€์ฒด๋จ.
  • Anemia (๋นˆํ˜ˆ) : ์•” ํ™˜์ž์—์„œ ํ”ํžˆ ๊ด€์ฐฐ๋จ. ์›์ธ์€ ๋‹ค์–‘.
  • Coagulopathies (์‘๊ณ ์žฅ์• ) : ํ”ํžˆ ๊ด€์ฐฐ๋จ. ํŠนํžˆ hemangiosarcoma ํ™˜์ž์—์„œ DIC๊ฐ€ ์ž˜ ๋‚˜ํƒ€๋‚จ.

6. The Molecular Basis of Cancer

  • Genetic changes (์œ ์ „์ฒด์˜ ๋ณ€ํ™”)
  • Epigenetic changes (์ƒ์œ ์ „์ฒด์˜ ๋ณ€ํ™”)
  • ๋‘˜ ์ค‘ ํ•˜๋‚˜ OR ๋‘˜ ๋‹ค์— ์˜ํ•ด ์•”์ด ๋ฐœ์ƒํ•œ๋‹ค.
  • driver mutations : ์ง์ ‘์ ์œผ๋กœ ์•” ๋ฐœ์ƒ์„ ์ด‰์ง„ํ•˜๊ฑฐ๋‚˜ ์–ต์ œํ•  ์ˆ˜ ์žˆ๋Š” ์œ ์ „์ž์˜ ๋Œ์—ฐ๋ณ€์ด
๋‚˜์ด์— ๋”ฐ๋ฅธ ์•” ๋ฐœ์ƒ ๋นˆ๋„ (dogs)
- ์œ ์„  ์ข…์–‘์„ ํฌํ•จํ•˜๋ฉด ํŒŒ๋ž€์ƒ‰, ๋ฐฐ์ œํ•˜๋ฉด ์ฃผํ™ฉ์ƒ‰ โ‡’ ๊ทธ๋งŒํผ ์œ ์„ ์ข…์–‘์˜ ์˜ํ–ฅ์ด ํฌ๋‹ค.
- ๋‚˜์ด๊ฐ€ ๋“ค์ˆ˜๋ก ์ฆ๊ฐ€ > ์˜ค๋žœ ์‹œ๊ฐ„์ด ํ•„์š”ํ•จ.

๐ŸŸข Genetic/Epigenetic Changes์˜ ์ข…๋ฅ˜

  • Genetic changes (์•”์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋Š” ์œ ์ „์  ๋ณ€์ด์˜ ์ข…๋ฅ˜)
    • Point mutation : ๋‹จ์ผ ์—ผ๊ธฐ์„œ์—ด ๋ณ€ํ™” (ex. A โ†’ G)
    • Gene amplification : ์œ ์ „์ž ๋ฐœํ˜„๋Ÿ‰์˜ ์ฆ๊ฐ€
    • Insertions/Deletions : (ํŠนํžˆ 1-2๊ฐœ์˜ ์—ผ๊ธฐ์„œ์—ด ๋ณ€ํ™”๋Š” stop codon์— ์˜ํ–ฅ์„ ์ค˜์„œ frameshift mutation์„ ์œ ๋ฐœ)
    • Aneuploidy(์ด์ˆ˜์„ฑ; 2n+1, 2n-1)/Translocations(์ „์ขŒ) : ์—ผ์ƒ‰์ฒด ์ด์ƒ ์œ ๋ฐœ
  • Epigenetic changes : DNA ์—ผ๊ธฐ์„œ์—ด์˜ ๋ณ€ํ™” ์—†์ด, ์œ ์ „์ž ๋ฐœํ˜„์ด ์กฐ์ ˆ๋˜๋Š” ๊ฒƒ
    • DNA methylation : DNA ์—ผ๊ธฐ(cytosine)์— ๋ฉ”ํ‹ธ๊ธฐ(-CH3)๊ฐ€ ๋ถ™์–ด ์œ ์ „์ž ๋ฐœํ˜„์„ ์–ต์ œํ•จ.

โœ… Oncogenes (โ€œAcceleratorโ€)

  • RAS genes : Growth factor๊ฐ€ ๋ถ€์ฐฉํ•˜๋ฉด ์ธ์‚ฐํ™”๋ฅผ ํ†ตํ•ด ํ™œ์„ฑํ™”๋˜์–ด ํŠน์ • ์œ ์ „์ž์˜ ๋ฐœํ˜„์„ ์ด‰์ง„ํ•จ.
  • RAS ์œ ์ „์ž์— mutation์ด ๋ฐœ์ƒํ•˜๋ฉด ํ•ญ์ƒ ํ™œ์„ฑํ™”๋œ ์ƒํƒœ๋กœ ์กด์žฌ โ†’ ๊ณ„์† ์œ ์ „์ž์˜ ๋ฐœํ˜„์„ ์ด‰์ง„ โ†’ ๊ทธ ์˜ํ–ฅ์„ ๋ฐ›์€ ์œ ์ „์ž๋“ค์ด ๋Œ€๋ถ€๋ถ„ oncogene์œผ๋กœ ์ž‘์šฉ
  • Tumor์˜ ์‹ ํ˜ธ๋งŒ ์„ ํƒ์ ์œผ๋กœ ์–ต์ œํ•˜๋Š” ๋ฐฉ๋ฒ•์„ ์•„์ง ๊ฐœ๋ฐœํ•˜์ง€ ๋ชปํ•ด์„œ ๋งˆ๋•…ํ•œ ์น˜๋ฃŒ์ œ๋Š” X

โœ… Tumor Suppressor Genes (โ€œBrakesโ€)

  • ๋Œ€ํ‘œ์ ์œผ๋กœ p53 (โ€œguardian of the genomeโ€)
    • p53์ด ์ •์ƒ์ ์œผ๋กœ ์ž‘๋™ํ•˜๋ฉด point mutation์ด ๋ฐœ์ƒํ•ด๋„ ์ •์ƒ์œผ๋กœ ๋˜๋Œ๋ฆฌ๋Š” ๊ณผ์ •์ด ์ž‘๋™ํ•˜๋Š”๋ฐ,
    • p53์— mutation์ด ์ถ•์ ๋˜๋ฉด ๋˜๋Œ์•„์˜ค์ง€ ๋ชปํ•จ โ†’ ์ข…์–‘ ์œ ๋ฐœ์˜ ์ค‘์š”ํ•œ ์ด‰์ง„์ž
  • repair๋ฅผ ๋‹ด๋‹นํ•˜๋Š” ๋‹ค๋ฅธ ์œ ์ „์ž๋“ค๋„ ๊ฒฐํ•/mutation์ด ์ƒ๊ธฐ๋ฉด ๋ณต๊ตฌ๋ฅผ ์–ด๋ ต๊ฒŒ ํ•ด์„œ ์•” ๋ฐœ์ƒ ํ™•๋ฅ ์„ ์ฆ๊ฐ€์‹œํ‚จ๋‹ค.
โž• Knudsonโ€™s โ€œTwo-Hitโ€ ๊ฐ€์„ค
์–‘์ชฝ ์ƒ๋™์„ธํฌ์— ๋‹ค mutation์ด ์ผ์–ด๋‚˜์•ผ ์œ ๋ฐœ๋˜๋Š” ์•”์—์„œ,
- ๋น„์œ ์ „์ ์ธ ์ƒํ™ฉ : 2๋ฒˆ์˜ hit์„ ๋ฐ›์•„์•ผ ์•”์ค„๊ธฐ์„ธํฌ๊ฐ€ ๋จ.
- ์œ ์ „์ ์ธ ์ƒํ™ฉ : hit์ด 1๋ฒˆ๋งŒ ๊ฐ€ํ•ด์ ธ๋„ ์•”์ด ๋  ์ˆ˜ ์žˆ์Œ.

์œ ์ „ ์†Œ์ธ์ด ์—†๋Š” ๊ฒฝ์šฐ ์•”์ด ๋งค์šฐ ์ฒœ์ฒœํžˆ, ๋“œ๋ฌผ๊ฒŒ ์ผ์–ด๋‚˜๋Š” ๋ฐ˜๋ฉด, ์œ ์ „ ์†Œ์ธ์ด ์žˆ๋Š” ๊ฒฝ์šฐ ์•”์ด ๋น„๊ต์  ํ”ํ•˜๊ฒŒ, ๋น ๋ฅด๊ฒŒ ์ผ์–ด๋‚œ๋‹ค๋Š” ๊ฐ€์„ค.

7. The Tumor Microenvironment & Immunity

๋ฏธ์„ธํ™˜๊ฒฝ(microenvironment) : ๋ฐ”๋กœ ์˜†์˜ ํ™˜๊ฒฝ(๊ธฐ์งˆ). (ex. ๋ฐ”๋กœ ์˜†์ž๋ฆฌ ์‚ฌ๋žŒ)

  • Parenchyma (์‹ค์งˆ) : ์‹ค์ œ ๊ธฐ๋Šฅํ•˜๋Š” ์„ธํฌ (์—ฌ๊ธฐ์„  neoplastic cells)
  • Stroma (๊ธฐ์งˆ) : ์ฃผ๋ณ€ ๊ตฌ์กฐ
    • ECM (Extracellular Matrix) : ๊ธฐ์งˆ์˜ ์ผ๋ถ€๋ถ„์ด๋ผ๋Š” ๊ฑธ ์•Œ์•„๋‘์ž.
    • Blood vessels : ์ข…์–‘์€ ํ˜ˆ๊ด€ํ™”๋ฅผ ์ด‰์ง„.
    • Fibroblast (์„ฌ์œ ์•„์„ธํฌ) : ํ˜ˆ๊ด€ํ™”์— ๊ด€์—ฌ, collagen(โŠƒECM) ํ•ฉ์„ฑ
    • ์ข…์–‘ ์ฃผ๋ณ€์— stroma๊ฐ€ ์–ผ๋งˆ๋‚˜ ์žˆ๋ƒ์— ๋”ฐ๋ผ ์ข…์–‘์ด ์–ผ๋งˆ๋‚˜ ๋” ์ž๋ž„ ์ˆ˜ ์žˆ๋Š”์ง€๊ฐ€ ๊ฒฐ์ •๋จ.
  • ํ˜ˆ๊ด€์€ ํ•ญ์ƒ ๊ธฐ์งˆ์— ์กด์žฌ (ํ”ผ๋ถ€๋กœ ๋”ฐ์ง€๋ฉด ์ง„ํ”ผ์ธต) โ†’ ์ข…์–‘์„ธํฌ๊ฐ€ ๊ธฐ์งˆ์— ๊ฐ€๊นŒ์ด ๊ฐˆ์ˆ˜๋ก ํ˜ˆ๊ด€ํ™”๋Š” ์ด‰์ง„๋จ.
  • ์ข…์–‘์„ธํฌ โ†” ๊ธฐ์งˆ์˜ ์ƒํ˜ธ์ž‘์šฉ์— ๋”ฐ๋ผ ์ฆ์‹์ด๋‚˜ ์นจ์Šต์ด ๊ฒฐ์ •๋จ.

๐ŸŸข Tumor-Stroma Interactions

  • ๋„์›€์ด ๋  ๋งŒํ•œ ๊ตฌ์กฐ๋ฌผ์€ ์ด‰์ง„์‹œํ‚ค๊ณ , ๋ฐฉํ•ด๋˜๋Š” ๊ตฌ์กฐ๋ฌผ์€ ์–ต์ œ์‹œํ‚ค๋Š” ์ƒํ˜ธ์ž‘์šฉ.

๐ŸŸข Angiogenesis (ํ˜ˆ๊ด€์‹ ์ƒ)

  • ํ˜ˆ๊ด€์€ ์˜์–‘๋ถ„ ๊ณต๊ธ‰ + ์ „์ด์˜ ํ†ต๋กœ.
  • ์–ด๋А ์ •๋„ ์ž๋ผ๋ฉด ํ˜ผ์ž ํž˜์œผ๋กœ๋Š” ์ฆ์‹ ๋ถˆ๊ฐ€ โ†’ ํ˜ˆ๊ด€์‹ ์ƒ ์œ ๋„ ๋ฌผ์งˆ์„ ๋ถ„๋น„ โ†’ ํ˜ˆ๊ด€๋‚ดํ”ผ์„ธํฌ๊ฐ€ ๋‹ค๊ฐ€์™€์„œ ์‹ ์ƒ ํ˜ˆ๊ด€์„ ์ƒ์„ฑ

๐ŸŸข Immunosurveillance

  • CD8์ด ์ค‘์‹ฌ ์—ญํ• : ๊ณต๊ฒฉํ•ด์•ผ ํ•  ๋Œ€์ƒ์„ ์ธ์‹ํ•จ.
    • CTL์ด ๊ณ„์† ํŠน์ • ํ•ญ์›์— ๋…ธ์ถœ๋˜๋‹ค ๋ณด๋ฉด self-antigen์œผ๋กœ ์ธ์‹ํ•˜์—ฌ ๊ณต๊ฒฉํ•˜์ง€ ์•Š์Œ. (= Immune tolerance)
    • ์ข…์–‘์„ธํฌ๊ฐ€ ๋ฐœํ˜„ํ•˜๋Š” ๋‹จ๋ฐฑ์งˆ์„ non-self๋กœ ์ธ์‹ํ•˜๋ฉด ๊ณต๊ฒฉํ•  ์ˆ˜ ์žˆ๊ฒŒ ๋จ.
  • Tumor cell๋“ค๋„ โ€˜non-selfโ€™๋กœ ์ธ์‹๋˜๋Š” ๊ฒƒ์„ ํ”ผํ•˜๊ธฐ ์œ„ํ•ด ๋‹ค์–‘ํ•œ ์ „๋žต์„ ๋ฐœํœ˜ํ•จ.

Tumor Antigens

  • ์ข…์–‘์„ธํฌ๋Š” tumor antigen์„ ๋ฐœํ˜„ํ•˜์—ฌ ๊ต๋ž€์‹œํ‚จ๋‹ค.

  • Tumor-Specific tumor cells

    • Mutated oncogens (e.g., mutated RAS) : ํ•ญ์ƒ ํ™œ์„ฑํ™”๋œ ์ƒํƒœ๋กœ ์„ธํฌ ์„ฑ์žฅ์„ ์ด‰์ง„
    • Mutated tumor suppressor genes (e.g., mutated p53) : ๊ณผ๋„ํ•œ ์ฆ์‹์„ ์–ต์ œํ•˜์ง€ ๋ชปํ•จ
      • p53 ์ž์ฒด๊ฐ€ ์ค„์–ด๋“  ๊ฒฝ์šฐ < ๋‹จ๋ฐฑ์งˆ๋Ÿ‰์€ ๊ทธ๋Œ€๋กœ but ๊ธฐ๋Šฅ์„ ๋ชปํ•˜๋Š”(mutated) p53 ์œ ์ „์ž์˜ ์ฆ๊ฐ€
  • mutated RAS :

    • ์ธ์‚ฐํ™” ํšจ์†Œ๊ฐ€ ์˜†์— ์žˆ๋Š” RAS ๋ฅผ ํ™œ์„ฑํ™” โ‡’ ๊ณ„์† ์ด‰์ง„ํ•จ (์„ฑ์žฅ ๊ด€๋ จ ์ธ์ž ์ด‰์ง„)
  • Tumor suppressor gene : ๊ณผ๋„ํ•œ ์„ธํฌ ์„ฑ์žฅ์„ ์–ต์ œํ•˜๊ณ  DNA repair์— ์ค‘์š”ํ•œ p53

    • mutated p53 ์ธ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Œ. p53์€ ์—ฌ์ „ํžˆ ๋งŽ์€๋ฐ ์ œ๋Œ€๋กœ ๊ธฐ๋Šฅ ๋ถˆ๊ฐ€.

Antitumor Mechanisms

Innate Immunity
NK cellsT lymphocyte์™€ ์œ ์‚ฌ. ์‚ฌ์ „ ๊ต์œก ์—†์ด๋„ tumor cell์„ ๊ณต๊ฒฉํ•˜๋Š” ์„ธํฌ.
- MHC class โ… ์„ ์ด์šฉ
Macrophagesํƒ์‹ํ•˜๋Š” ์ž‘์šฉ. ROS, RNS(reactive nitrogen species), ๋“ฑ์„ ๋ถ„๋น„ํ•จ. (๋ฌผ๋ฆฌ์  ํƒ์‹ + ๋ฌผ์งˆ์„ ๋ถ„๋น„ํ•ด์„œ ์ฃฝ์ž„)
- macrophage๋„ ๋ฌด์กฐ๊ฑด tumor cell์„ ์ฃฝ์ด๋Š” ์—ญํ• ๋งŒ ํ•˜์ง€ ์•Š๋Š”๋‹ค.
- M1, M2 macrophage๊ฐ€ ์žˆ๋Š”๋ฐ - M2 macrophage๋‚˜ tumor-associated macrophage์˜ ๊ฒฝ์šฐ tumor cell์ด ์‚ด์•„๋‚จ์„ ์ˆ˜ ์žˆ๊ฒŒ ๋„์™€์ฃผ๋Š” ๋ฌผ์งˆ์„ ๋ถ„๋น„ํ•จ. (!!)
Adaptive Immunity
CTLs
B lymphocytes

MHC ๊ฐ€ ํ‘œ์ง€์ž๋ฅผ ๊บผ๋‚ด๋†“๋Š”๋‹ค? ๊ผญ ๊ธฐ์–ตํ•˜๊ธฐ..

How Tumors Evade the Immune Responses

Tumor Immunotheraphy

  • melanoma๋ฅผ ์–ต์ œํ•˜๋Š” ๋ฐฉ์‹์˜ ๋ฐฑ์‹ 
  • melanocyte๋Š” tyrosinase๋ฅผ ๋งŒ๋“ฆ. (melanocyte๋Š” ํŠน์ด์ ์œผ๋กœ tyrosinase๋ฅผ ๋งŽ์ด ๋งŒ๋“ ๋‹ค. )
    • ์‚ฌ๋žŒ์˜ melanoma์—์„œ๋„
    • tyrosinase๋ฅผ ๋ฐœํ˜„ํ•  ์ˆ˜ ์žˆ๋Š” vector๋ฅผ ๋ฐฑ์‹ ์— ๋„ฃ์Œ โ‡’ ๋ฉด์—ญ์ฒด๊ณ„๊ฐ€ tyrosinase๋ฅผ ์ธ์‹ โ‡’ non-self๋ผ๊ณ  ์ธ์‹ํ•˜๊ฒŒ ๋จ.
    • ์›๋ž˜ ์ •์ƒ melanin cell๋„ tyrosinase๋ฅผ ๋งŒ๋“ค๊ณ , melanocyte๋Š” tyrosinase๋ฅผ ์ˆจ๊ฒจ์„œ self๋ผ๊ณ  ์ธ์‹ํ•จ.
    • but ์‚ฌ๋žŒ์˜ tyrosinase๋ฅผ ๊ฐ€์ ธ์™€์„œ non-self๋ผ๊ณ  ์ธ์‹ํ•˜๊ฒŒ ํ•จ.
    • ๊ทธ๋Ÿผ ๋ฉด์—ญ์ฒด๊ณ„๊ฐ€ tyrosinase๋ฅผ ๋งŒ๋“ค๊ณ  ์žˆ๋Š” melanoma๋ฅผ ๊ณต๊ฒฉํ•  ์ˆ˜ ์žˆ๊ฒŒ ๋จ.

(๋ณธ3-1) ๊น€๋‚ด2(A) - Canine Melanoma ๋‚ด์šฉ ไธญ Oncept ์•ฝ๋ฌผ ๊ด€๋ จ

  • ์ด๋ฆ„์€ ๋ฐฑ์‹ ์ด์ง€๋งŒ ์˜ˆ๋ฐฉ์ด ์•„๋‹ˆ๋ผ ๋ฉด์—ญ์„ ์œ ๋ฐœํ•ด์„œ ์น˜๋ฃŒํ•˜๋Š” ๋ฐฑ์‹ 
    • Melanin์„ ๋งŽ์ด ๋ถ„๋น„ํ•˜๋Š” ์ฃผ๋ฒ”์ธ, melanoma ์„ธํฌ ํ‘œ๋ฉด์˜ ๋‹น๋‹จ๋ฐฑ์งˆ(tyrosinase)์„ ๊ณต๊ฒฉํ•˜๋„๋ก ์œ ๋„ํ•˜๊ธฐ ์œ„ํ•ด genogenic(์ด์ข…)์˜ human DNA๋ฅผ ๊ฐœ์—๊ฒŒ ์ ‘์ข…ํ•จ.
    • ์‚ฌ๋žŒ๊ณผ ๊ฐœ์˜ tyrosinase๋Š” ๋งค์šฐ ๋น„์Šทํ•จ. ๊ฐœ์˜ DNA๋ฅผ ๋„ฃ์œผ๋ฉด ๋™์ข…์ด์–ด์„œ ๋ฉด์—ญ ํ˜•์„ฑ์ด ์•ˆ ๋˜์ง€๋งŒ, ์‚ฌ๋žŒ์˜ tyrosinase๋ฅผ vector์— ๋ผ์›Œ์„œ ์ฃผ์‚ฌํ•˜๋ฉด ์ด์— ๋Œ€ํ•œ ํ•ญ์ฒด๋ฅผ ๋งŒ๋“ค์–ด๋‚ด๋Š”๋ฐ, ๋งค์šฐ ๋น„์Šทํ•ด์„œ ๊ฐœ์˜ tyrosinase๋„ ๊ฐ™์ด ๊ณต๊ฒฉ๋จ.
  • ๋†’์€ ์ˆ˜์ค€์œผ๋กœ ๊ณผ๋ฐœํ˜„๋œ tyrosinase๋งŒ ๊ณต๊ฒฉํ•˜์ง€๋งŒ, ๋‚ฎ์€ ํ™•๋ฅ ๋กœ ๋ฐฑ๋ฐ˜์ฆ ์ƒ๊น€.
  • ํ˜„์žฌ ๊ฐœ์—์„œ ์Šน์ธ๋œ ์œ ์ผํ•œ ๋ฉด์—ญ ํ•ญ์•” ์น˜๋ฃŒ์ œ.

8. Causes of Cancer & Animal Models

Oncogenic Viruses

Pasted image 20251029113515.png

Naturally Occuring Tumors in Animals

9. Diagnosis and Prognosis

Malignancy๋ฅผ ํŒ๋‹จํ•˜๋Š” cytologic criteria

  • Anisocytosis (๋ถ€๋™์ฆ) [์„ธํฌ ํฌ๊ธฐ ๊ด€์ฐฐ]

  • (2) Anisokaryosis [ํ•ต์„ ๊ด€์ฐฐ]

    • Macrocytosis / Macrokaryosis : ํ•ต์ด ์–ผ๋งˆ๋‚˜ ํฐ์ง€
    • N:C ratio โ†‘ : ์ •์ƒ์ ์œผ๋กœ 1/4-1/5 ์ •๋„๋กœ ํ•ต์ด ์ž‘์•„์•ผ ํ•˜๋Š”๋ฐ, ์•…์„ฑ ์„ธํฌ์—์„œ๋Š” ํ•ต์ด ํ˜„์ €ํžˆ ํผ.
  • (3) Multiple/Prominent Nucleoli [์—ผ์ƒ‰์งˆ๊ณผ ์ธ ๊ด€์ฐฐ]

  • golden standard - ์‹ค์ œ๋กœ๋Š” ๊ณจ๋“  ์•„๋‹˜.. ์—ฌ์ „ํžˆ ์• ๋งค

    • ์‚ฌ์‹ค์ƒ excisional biopsy๋กœ ์ œ๋Œ€๋กœ ์ง„๋‹จ ๊ฐ€๋Šฅ
    • surgical margin evaluation : ์ ˆ์ œ ํ›„ ์™„์ „ ์ ˆ์ œ ํ•œ ๊ฒŒ ๋งž๋Š”์ง€ ํ™•์ธ. ์ด๊ฑฐ์•ผ๋ง๋กœ ์•„์ฃผ ์ค‘์š”ํ•œ !!

Tumor Grading

โ€œ ์˜ˆํ›„๋ฅผ ํŒ๋‹จ/์„ค๋ช…

Tumor Staging